Clear All
11564 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
69539-0020-99 69539-0020 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Jul 2, 2018 In Use
31722-0774-60 31722-0774 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Mar 5, 2024 In Use
00004-1101-75 00004-1101 Capecitabine Xeloda 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Apr 30, 1998 Dec 31, 2014 In Use
00378-2511-91 00378-2511 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Aug 8, 2014 Aug 31, 2023 No Longer Used
69097-0948-08 69097-0948 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Jul 1, 2023 In Use
65162-0843-06 65162-0843 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Mar 10, 2017 Feb 1, 2024 No Longer Used
72485-0204-60 72485-0204 Capecitabine Capecitabine 150mg 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Mar 1, 2019 In Use
00310-9501-95 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Feb 1, 2024 Oct 28, 2024 In Use
00310-9500-02 00310-9500 Capivasertib TRUQAP 160.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Oct 18, 2024 In Use
00310-9501-02 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Oct 18, 2024 In Use
00310-9501-96 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Oct 23, 2024 In Use
00310-9501-01 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Nov 16, 2023 In Use
00310-9500-01 00310-9500 Capivasertib TRUQAP 160.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Nov 16, 2023 In Use
00078-0716-56 00078-0716 Capmatinib TABRECTA 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0709-56 00078-0709 Capmatinib TABRECTA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0709-94 00078-0709 Capmatinib TABRECTA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0716-94 00078-0716 Capmatinib TABRECTA 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
57277-0105-05 57277-0105 carboplatin Injection Carboplatin 50.0 mg/5mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sep 29, 2016 In Use
57277-0106-15 57277-0106 carboplatin Injection Carboplatin 150.0 mg/5mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sep 29, 2016 In Use
57277-0107-45 57277-0107 carboplatin Injection Carboplatin 450.0 mg/5mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sep 29, 2016 In Use
47781-0603-20 47781-0603 Carboplatin CARBOPLATIN 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Mar 1, 2018 Aug 1, 2019 No Longer Used
25021-0202-05 25021-0202 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct 31, 2013 Nov 30, 2016 No Longer Used
16729-0295-34 16729-0295 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound INTRACAVERNOUS, Intravenous Sep 19, 2017 In Use
47335-0284-40 47335-0284 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Mar 3, 2014 In Use
61703-0150-05 61703-0150 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 23, 2022 In Use

Found 11564 results — Export these results